Solvonis Therapeutics Statistics
Solvonis Therapeutics (J4I) Stock Statistics & Valuation Metrics
Total Valuation
Solvonis Therapeutics has a market cap or net worth of EUR 8.52M. The enterprise value is EUR 11.32M.
- Market Cap
- EUR 8.52M
- Enterprise Value
- EUR 11.32M
Share Statistics
Solvonis Therapeutics has 7,899,737,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 7,899,737,000
- Owned by Insiders
- 5.26%
- Owned by Institutions
- ―
Financial Efficiency
Solvonis Therapeutics’s return on equity (ROE) is -0.93 and return on invested capital (ROIC) is -48.94%.
- Return on Equity (ROE)
- -0.93
- Return on Assets (ROA)
- -0.76
- Return on Invested Capital (ROIC)
- -48.94%
- Return on Capital Employed (ROCE)
- -0.49
- Revenue Per Employee
- 0
- Profits Per Employee
- -956.67K
- Employee Count
- 6
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Solvonis Therapeutics is -1.10. Solvonis Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.10
- PS Ratio
- 0.00
- PB Ratio
- 1.27
- Price to FCF
- -2.06
- Price to Operating Cash Flow
- -1.87
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Solvonis Therapeutics had revenue of 0 and earned -5.74M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.48M
- Pretax Income
- -5.74M
- Net Income
- -5.74M
- EBITDA
- -5.74M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -3.27M and capital expenditures 0, giving a free cash flow of -3.27M billion.
- Operating Cash Flow
- -3.27M
- Free Cash Flow
- -3.27M
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Solvonis Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -48.51%
- Earnings Yield
- -90.70%
Stock Price Statistics
- Beta
- -2.13
- 52-Week Price Change
- -92.81%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Solvonis Therapeutics upcoming earnings date is Jun 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 30, 2026
- Next Earnings Date
- Jun 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Solvonis Therapeutics as a current ratio of 4.00, with Debt / Equity ratio of 1.21%
- Current Ratio
- 4.00
- Quick Ratio
- 4.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.29
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Solvonis Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Solvonis Therapeutics EV to EBITDA ratio is -1.93, with an EV/FCF ratio of -1.88.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.93
- EV to Free Cash Flow
- -1.88
- EV to Operating Cash Flow
- -1.88
Balance Sheet
Solvonis Therapeutics has EUR 1.72M in cash and marketable securities with EUR 75.00K in debt, giving a net cash position of EUR 1.65M billion.
- Cash & Marketable Securities
- EUR 1.72M
- Total Debt
- EUR 75.00K
- Net Cash
- EUR 1.65M
- Net Cash Per Share
- EUR 0.00
- Tangible Book Value Per Share
- EUR 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%

